Increased Cancer Risk in Postmenopausal Women with Central Obesity

TON - November 2017, Vol 10, No 6 - Conference Correspondent
Phoebe Starr

Madrid, Spain—Central obesity increases the risk for developing cancer in postmenopausal women more than high body mass index (BMI) and fat percentage, according to a study reported at the 2017 European Society for Medical Oncology Congress.

“The findings put a new spin on weight management priorities for women in this age group, who are prone to abdominal weight gain. BMI and fat percentage may not be adequate measures of cancer risk,” said lead investigator Line Mærsk Staunstrup, MSc, PhD student, Department of Biomedical Sciences, University of Copenhagen, and Research Assistant, Nordic Bioscience A/S and ProScion, Herlev, Denmark.

The Prospective Epidemiological Risk Factor study enrolled 5855 women from 1999 to 2001. Mean age at enrollment was 71 years. Medical history and demographic information were collected, and a dual x-ray absorptiometry scan was performed to measure bone mass, bone-free lean mass, and fat mass.

Data were grouped according to breast and/or ovarian cancer, lung and/or gastrointestinal cancer, and other cancers. Cox proportional hazard regression models examined the association between body fat distribution and risk for cancer, adjusted for standard risk factors that included BMI.

Among 811 solid cancers, 293 breast and/or ovarian, 345 lung and/or gastrointestinal, and 173 other cancers were identified. In the overall study, central obesity was a significant predictor of cancer diagnosis (P <.001). BMI and fat percentage were not associated with cancer risk.

Analysis of the data in specific cancers found that central obesity was a significant risk factor for only lung and gastrointestinal cancer (P <.05).

“This information is useful for elderly women, as the transition to menopause is accompanied by a shift in body fat toward the central trunk area. Clinicians can use this information in conversations with women who are at higher risk of cancer,” Ms Staunstrup said.

Related Items
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Web Exclusives published on February 20, 2019 in Lung Cancer
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Web Exclusives published on February 11, 2019 in Leukemia
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients with CLL Under Age 70
Phoebe Starr
Web Exclusives published on February 7, 2019 in Leukemia
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
Web Exclusives published on January 28, 2019 in Breast Cancer
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
Web Exclusives published on November 20, 2018 in Emerging Therapies
Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Skin Cancer
Phoebe Starr
Web Exclusives published on November 13, 2018 in Immunotherapy
Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Web Exclusives published on October 22, 2018 in Breast Cancer
Immunotherapy Combinations “Raising the Bar”
Phoebe Starr
Web Exclusives published on October 16, 2018 in Immunotherapy
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Prostate Cancer
Last modified: December 8, 2017